^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Non Small Cell Lung Cancer
    Drug:Talzenna (talazoparib) (PARP inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ScienceDirect
    Title:

    A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficient Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400G)

    Published date:
    01/10/2021
    Excerpt:
    S1400G failed to show sufficient level of efficacy for single agent talazoparib in a biomarker defined subset of squamous lung cancer with HRRD.
    DOI:
    10.1016/j.cllc.2021.01.001
    Trial ID:
    Lung-MAP